Effect of Prophylactic Use of Silymarin on Hepatotoxicity Induced by Anti-tuberculosis Drugs
Status:
Unknown status
Trial end date:
2013-12-01
Target enrollment:
Participant gender:
Summary
Tuberculosis is a worldwide common infectious disease and effective first line
anti-tuberculosis (TB) drugs were available such as isoniazid, rifampicin, ethambutol, and
pyrazinamide. However, anti-TB drugs may induce hepatic injury resulting in discontinuation
of anti-TB drugs or changing anti-Tb drug regimen.
Silymarin has been widely studied for the effect on hepatitis and it has been used in
hepatology.
Therefore, the investigators hypothesized that prophylactic administration of silymarin with
anti-TB drugs may decrease the incidence and severity of hepatotoxicity induced by anti-TB
drugs.